

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Ascletis Pharma Inc.

歌禮製藥有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 1672)

NOTICE OF BOARD MEETING

The board of directors (the “**Board**”) of Ascletis Pharma Inc. (the “**Company**”) hereby announces that a meeting of the Board will be held on Wednesday, March 26, 2025 for the purpose of, among other matters, considering and approving the annual results of the Company and its subsidiaries for the year ended December 31, 2024 and its publication and considering the recommendation of payment of a final dividend (if any).

By order of the Board
Ascletis Pharma Inc.
歌禮製藥有限公司
Jinzi Jason WU
Chairman

Hangzhou, the People’s Republic of China
March 13, 2025

As at the date of this announcement, the Board comprises Dr. Jinzi Jason WU and Mrs. Judy Hejingdao WU, as executive Directors; and Dr. Yizhen WEI, Mr. Jiong GU and Ms. Lin HUA, as independent non-executive Directors.